Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 8/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550939 | 1.00 | KLK7 (0.48) | KLK7FKBP1ASTSNR1H2NR1H3 | |
| SCHEMBL1781452 | 0.90 | MCL1 (0.45) | KLK7FKBP1ANR1H2NR1H3 | |
| SCHEMBL1781450 | 0.90 | MCL1 (0.45) | KLK7FKBP1ANR1H2NR1H3 | |
| SCHEMBL4923969 | 0.90 | MCL1 (0.45) | KLK7FKBP1ANR1H2NR1H3 | |
| SCHEMBL28632436 | 0.86 | FKBP1A (0.50) | KLK7FKBP1AMEN1KMT2ACTSL | |
| SCHEMBL16064974 | 0.86 | FKBP1A (0.50) | KLK7FKBP1AMEN1KMT2ACTSL | |
| SCHEMBL29551303 | 0.86 | FKBP1A (0.50) | KLK7FKBP1AMEN1KMT2ACTSL | |
| SCHEMBL21066263 | 0.85 | KLK7 (0.47) | KLK7FKBP1ASTSNR1H2NR1H3 | |
| SCHEMBL29447560 | 0.84 | FKBP1A (0.58) | KLK7FKBP1AMEN1KMT2ANPC1 | |
| SCHEMBL7404715 | 0.84 | FKBP1A (0.58) | KLK7FKBP1AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119868377-A | Combination therapy for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-3921033-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2021-12-15 | — | — | EP | disclosed |
| CN-113395996-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2020161675-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2020-08-13 | — | — | WO | disclosed |